Apogee Therapeutics, Inc. (APGE) · Sep 3, 2026 · Acquisition

Apogee Therapeutics completes AbbVie’s $10.9B buyout, ending public trading

$10.9B acquisition — $135.11 cash per share; approximately $10.9B equity value

Apogee’s announced sale to AbbVie has closed at $135.11 per share, with delisting and leadership turnover now taking effect.

The closing was expected, not a fresh surprise. Apogee says the merger agreement was signed on June 18, 2026, and the transaction closed on September 3, 2026, so the market had already been working from a known cash-sale outcome rather than awaiting a clinical or financial update.

Deal termFiling detail
Cash consideration$135.11 per share (Merger Consideration)
Total equity valueApproximately $10.9 billion (Item 5.01)
Executive parachute gross-up cap$12.5 million (Item 5.02 / Exhibit 10.1)
Nasdaq trading suspensionSeptember 4, 2026 (Item 3.01)

The filing delivers the agreed economics in full. Each eligible share was converted into the right to receive $135.11 in cash, while options, restricted stock units, restricted stock and warrants were handled according to the merger terms.

Apogee is no longer an independent public company. AbbVie now owns Apogee indirectly and funded the approximately $10.9 billion equity transaction with cash on hand and debt; Apogee’s shareholders retain only the right to receive the merger consideration. 〔0〕

The remaining changes are administrative and organizational, not incremental value creation. Apogee requested delisting, trading is scheduled to be suspended on September 4, 2026, all existing directors resigned, and the executive officers ceased serving in their roles. 〔1〕 Because those consequences were inherent in the previously announced acquisition, this is best read as confirmation of a priced-in transaction rather than a new positive or negative catalyst.

What to watch next

Nasdaq delisting September 4; Form 15 filing to follow

Original filing on SEC EDGAR

More Apogee Therapeutics, Inc. news

Apogee Therapeutics completes AbbVie’s $10.9B buyout, ending public trading | APGE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.